Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

OBIZUR 500 U powder and solvent for solution for injection {equilateral_black_triangle}

Active Ingredient:
antihaemophilic factor , porcine factor viii:c , susoctocog alfa
Company:  
Takeda UK Ltd See contact details
ATC code: 
B02BD14
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{external_link}

Obizur reconstitution video

{healthcare_pro_orange} For Healthcare Professionals
Instruction video on reconstitution of Obizur
{pdf_link}

OBIZUR▼[antihaemophilic Factor VIII (recombinant), porcine sequence] HCP Brochure

{healthcare_pro_orange} For Healthcare Professionals
Information On Dose Calculation for OBIZURâ–¼[antihaemophilic Factor VIII (recombinant), porcine sequence]

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Takeda UK Ltd
Company image
Address
1 Kingdom Street, London, W2 6BD, UK
WWW
www.takeda.com/en-gb/
Telephone
+44 (0)3333 000 181
Medical Information e-mail
[email protected]
Drug Safety e-mail
[email protected]
Medical Information Direct Line
+44 (0)3333 000 181